Afamelanotide mastery course
Unit 10 of 12
How the implant is administered
Afamelanotide is given as a 16 mg controlled-release implant placed under the skin by a clinician, roughly every two mo…
The approved protocol, and what gray-market use is not
Afamelanotide is given as a 16 mg controlled-release implant placed under the skin by a clinician, roughly every two months during the sun-exposure season. This unit explains that approved protocol and the pharmacokinetic logic behind it.
It then clearly separates what the gray-market does, reconstituting and injecting powder, as something reported, not endorsed. This is education only, not a protocol, and afamelanotide is clinician-administered by design.